Drug ID:Drug184
Drug Name:GLPG3970
CID:146273261
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT04577794
Molecular Formula:C25H27F3N4O4
Molecular Weight:504.5 g/mol
Isomeric SMILES:COC1=CC(=CC2=C1C(=O)N(CC2)CC(F)(F)F)C3=CN=C4N3C=CC(=C4)OCCN5CCOCC5
Synonyms:GLPG3970; 2403733-82-2; GLPG-3970; UA6B2TI4MO; UNII-UA6B2TI4MO; 8-methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one; CHEMBL5393771; 1(2H)-Isoquinolinone, 3,4-dihydro-8-methoxy-6-(7-(2-(4-morpholinyl)ethoxy)imidazo(1,2-a)pyridin-3-yl)-2-(2,2,2-trifluoroethyl)-; 8-Methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one; SCHEMBL21591149
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1309 146273261 8-Methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one 23235 SIK2 Homo sapiens (human) Inhibition
dt1310 146273261 8-Methoxy-6-{7-[2-(morpholin-4-yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one 23387 SIK3 Homo sapiens (human) Inhibition

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04577794 A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis PHASE2 COMPLETED Galapagos NV Ulcerative Colitis DRUG: GLPG3970|DRUG: Placebo Details
NCT04624230 Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis PHASE3 RECRUITING Pfizer Ulcerative Colitis DRUG: tofacitinib Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis PHASE3 TERMINATED InDex Pharmaceuticals Ulcerative Colitis DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients PHASE2 ACTIVE_NOT_RECRUITING CannaMore Biotechs Ulcerative Colitis DRUG: CBD, synthetic form|DRUG: Placebo Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT01011322 A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis PHASE2 UNKNOWN Lipid Therapeutics GmbH Ulcerative Colitis|Large Intestine|Diarrhea|Abdom… DRUG: LT-02|DRUG: placebo Details
NCT02610569 Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis None COMPLETED Dr. Arnaud Bourreille Ulcerative Colitis DEVICE: standard endoscopy|DEVICE: PillCamCOLON (… Details
NCT06109441 Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics PHASE2 RECRUITING AltruBio Inc. Ulcerative Colitis BIOLOGICAL: ALTB-268 Details
NCT06420492 Study of Novel Therapeutics for Acute Remedy of Colitis PHASE2 NOT_YET_RECRUITING Brigham and Women's Hospital Ulcerative Colitis|Ulcerative Colitis Chronic Mod… DRUG: BRS201 Details
NCT02039505 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis PHASE3 COMPLETED Takeda Ulcerative Colitis DRUG: Vedolizumab|DRUG: Vedolizumab placebo Details
NCT02392221 Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). None COMPLETED Centre Hospitalier Universitaire, Amiens Pediatric Inflammatory Bowel Disease None Details
NCT05907330 Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis PHASE2 NOT_YET_RECRUITING Curacle Co., Ltd. Ulcerative Colitis DRUG: CU104|DRUG: Placebo Details
NCT01100112 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets PHASE3 COMPLETED Bausch Health Americas, Inc. Colitis, Ulcerative DRUG: Budesonide Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT03832400 Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC) PHASE1 COMPLETED NuBiyota Ulcerative Colitis BIOLOGICAL: MET-2|DRUG: Placebo oral capsule Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations